Expect a positive short-term reaction as ASCO data de-risk LB2102 and reinforce CARVYKTI's durability. Near-term upside potential from pipeline re-rating. Monitor for further phased data and potential milestone payments from Novartis.
Price Chart
Executive Summary
Legend Biotech presented first-in-human Phase 1 data for LB2102 (DLL3-targeted CAR-T) in solid tumors at ASCO 2026, showing an ORR of 28.6% at the highest dose level and a manageable safety profile. New CARVYKTI data reinforced durable efficacy with 30-month OS >85% in CARTITUDE-4 responders. The filing validates Legend's pipeline expansion beyond multiple myeloma and supports the commercial franchise.
Key Facts
- LB2102 Phase 1 overall ORR: 20% (4/20); at dose level 3: ORR 28.6%, DCR 78.6%.
- LB2102 showed no dose-limiting toxicities or treatment-related deaths; all CRS were Grade 2.
- CARVYKTI CARTITUDE-4 subgroup analysis: 30-month OS >85% in responders; no IEC-associated Parkinsonism.
- CARVYKTI is commercially available in 18 countries and has treated >10,000 patients.
- LB2102 is licensed to Novartis under a 2023 agreement; Legend conducts the US Phase 1 trial.
Financial Impact
Not directly quantified; positive readout could accelerate LB2102 development milestones and support CARVYKTI uptake.
Risk Factors
- LB2102 is early phase (n=20); larger trials may not confirm efficacy.
- CAR-T in solid tumors faces biological hurdles; safety signals (ICANS, CRS) remain elevated.
- Competition from other BCMA and DLL3-targeted therapies could limit commercial opportunity.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001171843-26-003825 |
| Document: f6k_060126.htm | 0001171843-26-003825 |
| Document: 0001171843-26-003825-index-headers.html | 0001171843-26-003825 |
| Document: 0001171843-26-003825-index.html | 0001171843-26-003825 |
| Document: 0001171843-26-003825.txt | 0001171843-26-003825 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 15, 2026 11d ago | 6-K | $19.80 | awaiting T+20 | — | $20.39 (+2.98%) |
Oct 13, 2026 13d ago | 6-K | $17.88 | awaiting T+20 | — | $20.39 (+14.04%) |
Sep 29, 2026 27d ago | 144 | $18.82 | awaiting T+20 | — | $20.39 (+8.34%) |
Sep 25, 2026 4w ago | 6-K | $19.11 $19.27 | ▲ +0.84% | ▲ +2.31% | $20.39 (+6.70%) |
Sep 25, 2026 4w ago | Press Release | $19.11 $19.27 | ▲ +0.84% | ▲ +2.31% | $20.39 (+6.70%) |
Sep 15, 2026 5w ago | 6-K | $17.67 $17.88 | ▲ +1.19% | ▼ −1.53% | $20.39 (+15.39%) |
Sep 14, 2026 6w ago | 6-K | $18.53 $17.80 | ▼ −3.94% | ▼ −6.20% | $20.39 (+10.04%) |
Aug 11, 2026 10w ago | 6-K | $21.83 $19.91 | ▼ −8.80% | ▼ −7.74% | $20.39 (−6.60%) |
Jul 27, 2026 13w ago | 6-K | $19.27 $20.94 | ▼ −8.67% | ▼ −5.37% | $20.39 (−5.81%) |
Jul 27, 2026 13w ago | Press Release | $19.27 $20.94 | ▲ +8.67% | ▲ +5.37% | $20.39 (+5.81%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers